9
Active INDs
4
Technology Platforms
600
Employees

Recent News

Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer

Athenex, Inc. Announces Second Quarter 2019 Financial Results, Positive Phase III Results on Oral Paclitaxel plus Encequidar and Increased Product Sales Guidance

Athenex Provides an Update Regarding the Vasopressin Case

Athenex, Inc. to Report Second Quarter 2019 Earnings Results on August 7, 2019

Athenex Announces Strategic Global Initiatives to Expand Clinical Operations

Athenex Announces U.S. FDA Allowance of Investigational New Drug Application for PT01 (Pegtomarginase)

Athenex and PharmaEssentia Announce Positive Early Signals of Clinical Activity of KX2-391 (INN: tirbanibulin) in Patients with Psoriasis

Athenex and PharmaEssentia Announce Positive Early Signals of Clinical Activity of KX2-391 (INN: tirbanibulin) in Patients with Psoriasis

Athenex to Present at the 2019 ASCO Annual Meeting

Other Highlights

Photography by Christopher Galluzzo / Nasdaq, Inc.

Photography by Christopher Galluzzo / Nasdaq, Inc.

On June 14, 2017, Athenex celebrated its initial public offering (IPO) at the Nasdaq MarketSite in Times Square.

Athenex is building a 409,000 square foot manufacturing facility in Dunkirk, NY, with support from New York State.